Genetec Bilan de santé

Santé financière contrôle des critères 5/6

Genetec possède un total de capitaux propres de ¥2.1B et une dette totale de ¥925.0M, ce qui porte son ratio d'endettement à 44%. Son actif total et son passif total sont ¥4.4B et de ¥2.3B. L'EBIT de Genetec est ¥805.0M ce qui fait que son ratio de couverture des intérêts 100.6. Elle dispose de liquidités et de placements à court terme de ¥1.2B.

Informations clés

44.0%

Ratio d'endettement

JP¥925.00m

Dette

Ratio de couverture des intérêts	100.6x
Argent liquide	JP¥1.24b
Fonds propres	JP¥2.10b
Total du passif	JP¥2.28b
Total des actifs	JP¥4.38b

Mises à jour récentes de la santé financière

Is Genetec (TSE:4492) Using Too Much Debt?

Nov 11

Does Genetec (TSE:4492) Have A Healthy Balance Sheet?

Aug 02

Recent updates

Is Genetec (TSE:4492) Using Too Much Debt?

Nov 11

Positive Sentiment Still Eludes Genetec Corporation (TSE:4492) Following 34% Share Price Slump

Aug 05

Does Genetec (TSE:4492) Have A Healthy Balance Sheet?

Aug 02

Genetec Corporation's (TSE:4492) Popularity With Investors Under Threat As Stock Sinks 27%

May 23

Genetec Corporation (TSE:4492) Stock Rockets 38% As Investors Are Less Pessimistic Than Expected

Feb 26

Capital Allocation Trends At Genetec (TYO:4492) Aren't Ideal

Mar 28

Genetec Corporation (TYO:4492) Has A ROE Of 13%

Nov 23

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 4492 ( ¥3.0B ) dépassent ses passifs à court terme ( ¥1.7B ).

Passif à long terme: Les actifs à court terme de 4492 ( ¥3.0B ) dépassent ses passifs à long terme ( ¥540.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 4492 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 4492 est passé de 20% à 44% au cours des 5 dernières années.

Couverture de la dette: La dette de 4492 est bien couverte par le flux de trésorerie opérationnel ( 65.1% ).

Couverture des intérêts: Les paiements d'intérêts de 4492 sur sa dette sont bien couverts par l'EBIT ( 100.6 x couverture).

Genetec Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Is Genetec (TSE:4492) Using Too Much Debt?

Does Genetec (TSE:4492) Have A Healthy Balance Sheet?

Recent updates

Is Genetec (TSE:4492) Using Too Much Debt?

Now 21% undervalued after recent price drop

Genetec Corporation to Report Q2, 2025 Results on Nov 14, 2024

Upcoming dividend of JP¥8.00 per share

Now 21% undervalued after recent price drop

First quarter 2025 earnings released: EPS: JP¥4.56 (vs JP¥1.67 loss in 1Q 2024)

Positive Sentiment Still Eludes Genetec Corporation (TSE:4492) Following 34% Share Price Slump

New major risk - Share price stability

Does Genetec (TSE:4492) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 15%

Genetec Corporation to Report Q1, 2025 Results on Aug 09, 2024

Genetec Corporation's (TSE:4492) Popularity With Investors Under Threat As Stock Sinks 27%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Genetec Corporation, Annual General Meeting, Jun 25, 2024

Investor sentiment deteriorates as stock falls 21%

Genetec Corporation to Report Fiscal Year 2024 Results on May 15, 2024

Upcoming dividend of JP¥6.50 per share

Genetec Corporation (TSE:4492) Stock Rockets 38% As Investors Are Less Pessimistic Than Expected

Third quarter 2024 earnings released

Investor sentiment improves as stock rises 18%

New major risk - Share price stability

Investor sentiment improves as stock rises 20%

New major risk - Share price stability

Genetec Corporation to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released

Investor sentiment improves as stock rises 25%

Genetec Corporation to Report Q2, 2024 Results on Nov 14, 2023

First quarter 2024 earnings released: JP¥5.02 loss per share (vs JP¥34.94 loss in 1Q 2023)

Genetec Corporation to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥10.00 per share at 2.0% yield

Third quarter 2023 earnings released: JP¥13.22 loss per share (vs JP¥1.87 loss in 3Q 2022)

Genetec Corporation (TSE:4492) agreed to acquire Topwell Co., Ltd. from Yasuhide Inoue for ¥547 million.

Genetec Corporation to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released

Less than half of directors are independent

Genetec Corporation to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: JP¥34.94 loss per share (vs JP¥19.20 profit in 1Q 2022)

Genetec Corporation to Report Q1, 2023 Results on Aug 10, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Genetec Corporation, Annual General Meeting, Jun 28, 2022

No independent directors

Genetec Corporation to Report Fiscal Year 2022 Results on May 16, 2022

Upcoming dividend of JP¥10.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Genetec Corporation (JASDAQ:4492) agreed to acquire BART Co., Ltd. from Hitoshi Fujita and others.

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS JP¥4.02 (vs JP¥8.13 in 2Q 2021)

Upcoming dividend of JP¥4.00 per share

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS JP¥94.39 (vs JP¥141 in FY 2020)

Capital Allocation Trends At Genetec (TYO:4492) Aren't Ideal

Upcoming dividend of JP¥8.00 per share

New 90-day low: JP¥1,846

New 90-day low: JP¥1,926

Genetec Corporation (TYO:4492) Has A ROE Of 13%

New 90-day high: JP¥2,421

New 90-day low - JP¥1,542

Genetec Corporation to Report Q1, 2021 Results on Aug 05, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines